Table 1 Primary characteristics of patients and controls
Entity | n | Male (n/%) | Female (n/%) | Age (mean ± SD) | Stage limited/advanced/unknown (n/%) |
|---|---|---|---|---|---|
All tumors | 145 | 89 (61.4%) | 56 (38.6%) | 58.8 ± 14.70 | 28 (19.3%)/62 (42.8%)/55 (37.9%) |
Adrenal cancers | 31 | 13 (41.9%) | 18 (58.1%) | 51.3 ± 9.97 | 5 (16.1%)/19 (61.3%)/7 (22.6%) |
Atypical carcinoid of lung | 1 | 0 (0.0%) | 1 (100.0%) | 58.0 ± 0.00 | 0 (0.0%)/0 (0.0%)/1 (100.0%) |
Breast cancer (non-neuroendocrine) | 2 | 0 (0.0%) | 2 (100.0%) | 59.5 ± 1.50 | 0 (0.0%)/0 (0.0%)/2 (100.0%) |
Cholangiocarcinoma | 4 | 3 (75.0%) | 1 (25.0%) | 70.3 ± 5.17 | 1 (25.0%)/2 (50.0%)/1 (25.0%) |
Colorectal cancer | 1 | 1 (100.0%) | 0 (0.0%) | 60.0 ± 0.00 | 1 (100.0%)/0 (0.0%)/0 (0.0%) |
CUP (non-neuroendocrine) | 3 | 1 (33.3%) | 2 (66.7%) | 74.3 ± 8.06 | 0 (0.0%)/2 (66.7%)/1 (33.3%) |
DSRCT | 9 | 9 (100.0%) | 0 (0.0%) | 29.4 ± 8.90 | 0 (0.0%)/0 (0.0%)/9 (100.0%) |
Ewing’s sarcoma | 1 | 1 (100.0%) | 0 (0.0%) | 53.0 ± 0.00 | 0 (0.0%)/1 (100.0%)/0 (0.0%) |
Granulosa cell tumor | 1 | 0 (0.0%) | 1 (100.0%) | 72.0 ± 0.00 | 1 (100.0%)/0 (0.0%)/0 (0.0%) |
Hepatocellular carcinoma | 6 | 3 (50.0%) | 3 (50.0%) | 61.3 ± 7.16 | 3 (50.0%)/1 (16.7%)/2 (33.3%) |
Laryngeal cancer | 1 | 1 (100.0%) | 0 (0.0%) | 72.0 ± 0.00 | 0 (0.0%)/0 (0.0%)/1 (100.0%) |
Malignant paraganglioma | 1 | 1 (100.0%) | 0 (0.0%) | 49.0 ± 0.00 | 0 (0.0%)/1 (100.0%)/0 (0.0%) |
MANEC | 2 | 1 (50.0%) | 1 (50.0%) | 65.5 ± 2.50 | 0 (0.0%)/2 (100.0%)/0 (0.0%) |
Melanoma | 2 | 2 (100.0%) | 0 (0.0%) | 66.0 ± 4.00 | 0 (0.0%)/0 (0.0%)/2 (100.0%) |
Mesothelioma | 6 | 5 (83.3%) | 1 (16.7%) | 69.3 ± 9.59 | 1 (16.7%)/2 (33.3%)/3 (50.0%) |
Neuroendocrine tumors | 25 | 17 (68.0%) | 8 (32.0%) | 66.3 ± 10.57 | 3 (12.0%)/14 (56.0%)/8 (32.0%) |
NSCLC | 9 | 8 (88.9%) | 1 (11.1%) | 59.3 ± 8.56 | 4 (44.4%)/5 (55.6%)/0 (0.0%) |
Osteosarcoma | 1 | 1 (100.0%) | 0 (0.0%) | 32.0 ± 0.00 | 1 (100.0%)/0 (0.0%)/0 (0.0%) |
Ovarial cancer | 1 | 0 (0.0%) | 1 (100.0%) | 73.0 ± 0.00 | 1 (100.0%)/0 (0.0%)/0 (0.0%) |
Pancreatic adenocarcinoma | 9 | 6 (66.7%) | 3 (33.3%) | 65.3 ± 12.89 | 2 (22.2%)/1 (11.1%)/6 (66.7%) |
Prostate cancer | 2 | 2 (100.0%) | 0 (0.0%) | 64.0 ± 8.00 | 0 (0.0%)/1 (50.0%)/1 (50.0%) |
Renal cell carcinoma | 4 | 3 (75.0%) | 1 (25.0%) | 71.8 ± 12.75 | 1 (25.0%)/2 (50.0%)/1 (25.0%) |
Sarcoma | 7 | 3 (42.9%) | 4 (57.1%) | 45.7 ± 18.90 | 2 (28.6%)/1 (14.3%)/4 (57.1%) |
Salivary gland cancer | 1 | 1 (100.0%) | 0 (0.0%) | 52.0 ± 0.00 | 0 (0.0%)/0 (0.0%)/1 (100.0%) |
SCLC | 13 | 6 (46.2%) | 7 (53.8%) | 62.2 ± 11.41 | 2 (15.4%)/7 (53.8%)/4 (30.8%) |
Thyroid cancer | 1 | 1 (100.0%) | 0 (0.0%) | 61.0 ± 0.00 | 0 (0.0%)/1 (100.0%)/0 (0.0%) |
Undifferentiated cancer of thymus | 1 | 0 (0.0%) | 1 (100.0%) | 41.0 ± 0.00 | 0 (0.0%)/0 (0.0%)/1 (100.0%) |
Controls | |||||
Conn’s adenom | 3 | 3 (100.0%) | 0 (0.0%) | 57.7 ± 7.93 | n.a |
Healthy controls | 2 | 1 (50.0%) | 1 (50.0%) | 65.5 ± 2.50 | n.a |